Literature DB >> 31291615

Intestinal Behçet's Disease with Primary Myelofibrosis Involving Trisomy 8.

Taisuke Narazaki1, Motoaki Shiratsuchi2, Mariko Tsuda1, Yasuhiro Tsukamoto1, Hiroki Muta1, Toru Masuda1, Daisaku Kimura1, Akiko Takamatsu1, Ryota Nakanishi3, Eiji Oki3, Minako Fujiwara4, Yoshinao Oda4, Yasuhiro Nakashima1, Yoshihiro Ogawa1,5.   

Abstract

Behçet's disease (BD) is a disorder characterized by systemic inflammation of multiple organs, including the intestines. Several studies have reported a relationship between myelodysplastic syndrome and BD, and trisomy 8 was frequently seen, especially in intestinal BD. However, the association of BD with primary myelofibrosis (PMF) has not been well documented. A 58-year-old Japanese female was diagnosed with PMF in 2014. The symptoms of PMF resolved with ruxolitinib. However, she developed fever and intestinal perforation due to multiple ulcers in the terminal ileum in 2017. Intestinal perforation recurred 1 month later, and the dose of ruxolitinib was tapered. After discontinuation of ruxolitinib, she presented with recurrent oral aphthous ulcers and uveitis. Subsequently, intestinal perforation recurred, and she was diagnosed with intestinal BD. Trisomy 8 was identified in her peripheral blood. She underwent steroid therapy, azathioprine, and infliximab. This case suggests relationships between PMF, trisomy 8, and BD.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Behçet’s disease; Infliximab; Intestinal ulcer; Primary myelofibrosis; Trisomy 8

Year:  2019        PMID: 31291615     DOI: 10.1159/000501019

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  2 in total

1.  JAK-inhibition as a therapeutic strategy for refractory primary systemic vasculitides.

Authors:  Sujoy Khan
Journal:  Clin Med (Lond)       Date:  2021-03       Impact factor: 2.659

2.  Trisomy 8-positive Polycythemia Vera Complicated with Intestinal Behçet's-like Disease: A New Perspective for a Clinical Approach.

Authors:  Yuki Mori; Fumihiko Iwamoto; Toru Kuno; Shoji Kobayashi; Takashi Yoshida; Tatsuya Yamaguchi; Shinichi Takano; Tetsuo Kondo; Keita Kirito; Nobuyuki Enomoto
Journal:  Intern Med       Date:  2021-11-06       Impact factor: 1.282

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.